QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT ID: NCT03510897

Last Updated: 2021-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1043 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-29

Study Completion Date

2021-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo-controlled, Phase 3 trial to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events in subjects at high risk for acute kidney injury following cardiac surgery. Subjects will be dosed with active drug or placebo after the completion of cardiovascular surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

QPI-1002

QPI-1002 Injection, Single dose

Group Type ACTIVE_COMPARATOR

teprasiran

Intervention Type DRUG

IV injection

Placebo

isotonic saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

isotonic saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

teprasiran

IV injection

Intervention Type DRUG

Placebo

isotonic saline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

QPI-1002

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, age ≥ 18 years old
* At risk for AKI following cardiac surgery on the basis of at least one of the following pre-operatively assessed risk factors:

* Reduced renal function
* Diabetes with ongoing insulin treatment
* Albuminuria
* Undergoes non-emergent open chest cavity cardiovascular surgeries, with use of cardiopulmonary bypass (CPB), with or without hypothermic circulatory arrest

Exclusion Criteria

* Emergent surgeries, including aortic dissection, and major congenital heart defects
* Undergoes cardiac surgery off CPB for subjects ≥45 years old. (Cardiac surgery off CPB for subjects \<45 years old is allowed.)
* Perioperative or post cardiac surgery, an left ventricular assist device (LVAD) is inserted or anticipated
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Quark Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nitsan Halevy, MD

Role: STUDY_DIRECTOR

Quark Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham Hospital

Birmingham, Alabama, United States

Site Status

Keck Hospital of USC

Los Angeles, California, United States

Site Status

Cedar-Sinai Heart Institute

Los Angeles, California, United States

Site Status

Ronald Regan UCLA Medical Center

Los Angeles, California, United States

Site Status

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

River City Clinical Research

Jacksonville, Florida, United States

Site Status

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Site Status

Emory Saint Joseph's Hospital

Atlanta, Georgia, United States

Site Status

Northwestern University

Evanston, Illinois, United States

Site Status

Indiana/ Ohio Heart, a division of Luthern Medical Group, LLC

Fort Wayne, Indiana, United States

Site Status

Indiana University Health-Methodist Hospital

Indianapolis, Indiana, United States

Site Status

University of Kentucky Healthcare

Lexington, Kentucky, United States

Site Status

University of Louisville Physicians (ULP)

Louisville, Kentucky, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

MidMichigan Medical Center Midland

Midland, Michigan, United States

Site Status

Cardiac & Vascular Research Center of Northern Michigan

Petoskey, Michigan, United States

Site Status

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status

Bryan Heart

Lincoln, Nebraska, United States

Site Status

Nebraska Heart Hospital

Lincoln, Nebraska, United States

Site Status

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Saint Barnabas Medical Center

Livingston, New Jersey, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Mission Hospital, Inc.

Asheville, North Carolina, United States

Site Status

Duke University Hospital Medical Center

Durham, North Carolina, United States

Site Status

East Carolina Heart Institute at East Carolina University

Greenville, North Carolina, United States

Site Status

Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, United States

Site Status

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Baylor Jack and Jane Hamilton Heart and Vascular Hospital - Soltero Cardiovasular

Dallas, Texas, United States

Site Status

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

University of Utah Health

Salt Lake City, Utah, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States

Site Status

University Hospital

Madison, Wisconsin, United States

Site Status

Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, United States

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

The Prince Charles Hospital

Chermside, Qeensland, Australia

Site Status

Princess Alexandra Hospital

Woolloongabba, Qeensland, Australia

Site Status

The Townsville Hospital

Douglas, Queensland, Australia

Site Status

Flinders Medical Centre

Bedford Park, South Australia, Australia

Site Status

Monash Medical Centre

Clayton, Victoria, Australia

Site Status

St. Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

Site Status

Austin Hospital

Heidelberg, Victoria, Australia

Site Status

The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

Medizinische Universitat Innsbruck

Innsbruck, Tyrol, Austria

Site Status

Kepler Universitatsklinikum GmbH

Linz, Upper Austria, Austria

Site Status

Medizinische Universitat Wien

Vienna, , Austria

Site Status

University Hospital Leuven, Campus Gasthuisberg

Leuven, , Belgium

Site Status

Foothills Medical Centre, Libin Cardiovascular Institute of Alberta, University of Calgary

Calgary, Alberta, Canada

Site Status

University of Alberta Hospital / Mazankowski Alberta Heart Institute

Edmonton, Alberta, Canada

Site Status

Royal Jubilee Hospital (Victoria Island Health Authority)

Victoria, British Columbia, Canada

Site Status

St. Boniface Hospital

Winnipeg, Manitoba, Canada

Site Status

Horizon Health Network, Saint John Regional Hospital

Saint John, New Brunswick, Canada

Site Status

Hamilton General Hospital

Hamilton, Ontario, Canada

Site Status

London Health Sciences Center, University Hospital

London, Ontario, Canada

Site Status

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, Canada

Site Status

McGill University Health Center - Royal Victoria Hospital

Montreal, Quebec, Canada

Site Status

Institut Universitaire de cardiologie et de pneomologie de Quebec, Universite Laval

Québec, Quebec, Canada

Site Status

Fakulni nemocnice Hradec Kralove, Kardiochirurgicka klinika

Hradec Králové, , Czechia

Site Status

Institut klinicke a experimenalni mediciny, Klinika kardiovaskularni chirurgie

Prague, , Czechia

Site Status

Fakultni nemocnice Motol a 2. LF UK, Klinika kariovaskularni chirurgie 2. LF. UK

Prague, , Czechia

Site Status

CHU Besancon-Service de Chirurgie Thoracique et Cardiovasculaire

Besançon, , France

Site Status

CHU - Grenoble Alpes

Grenoble, , France

Site Status

CHU Bordeaux

Pessac, , France

Site Status

Hospital Robert Debre

Reims, , France

Site Status

Chu Pontchaillou Rennes

Rennes, , France

Site Status

Hopitaux Universitaires de Strasbourg - Service de Chirurgie Cardiovasculaire

Strasbourg, , France

Site Status

CHU Toulouse - Hospital Rangueil-Service de Chirurgie Cadriovasculaire

Toulouse, , France

Site Status

Deutsches Herzzentrum Munchen

München, Bavaria, Germany

Site Status

Charite-Universitatsmedizin Berlin

Berlin, Brandenburg, Germany

Site Status

Klinikum der Friedrich-Schiller-Universitat Jena

Jena, Deutschland, Germany

Site Status

Universitatsklinikum Frankfurt am Main

Frankfurt am Main, Hesse, Germany

Site Status

Universitasklinikum Giessen und Marburg GmbH

Geißen, Hesse, Germany

Site Status

Herz-Und Gefasszentrum Bad Bevensen

Bad Bevensen, Lower Saxony, Germany

Site Status

Krankenhaus der Barmherzigen Bruder Trier

Trier, Rhineland-Palatinate, Germany

Site Status

Herzzentrum Leipzig

Leipzig, Saxony, Germany

Site Status

Universitats-Herzzentrum Freiburg-Bad Krozingen

Bad Krozingen, , Germany

Site Status

RHON-KLINIKUM Campus Bad Neustadt

Bad Neustadt an der Saale, , Germany

Site Status

Deutsches Herzzentrum Berlin

Berlin, , Germany

Site Status

Universitatsklinikum Bonn

Bonn, , Germany

Site Status

Universitatsklinikum "Carl Gustav Carus" der Technischen Universitat Dresden Klinik fur Herzchirurgle

Dresden, , Germany

Site Status

Universitatklinicum Essen Westdeutsches Herzzentrum Essen

Essen, , Germany

Site Status

Universitatsklinikum Heidelberg und Medizinische Fakultat

Heidelberg, , Germany

Site Status

Universitatsklinikum Schleswig-Holstein, Campus Lubeck

Lübeck, , Germany

Site Status

Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Mainz, , Germany

Site Status

Herzchirurgische Klinik und Poliklinik

München, , Germany

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Wellington Regional Hospital

Wellington, , New Zealand

Site Status

Hospital Clinico Universitario de Santiago-CHUS

Santiago de Compostela, A Coruña, Spain

Site Status

Hospital Universitario Germans Trias i Pujol

Badalona, Barcelona, Spain

Site Status

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital Universitario Reina Sofia

Córdoba, Cordoba, Spain

Site Status

Complejo Hospitalario de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital Universitario de Cruces

Barakaldo, , Spain

Site Status

Hospital Universitario de la Princesa

Madrid, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario Central de Asturias

Oviedo, , Spain

Site Status

Hospital Clinic Universitario de Valencia

Valencia, , Spain

Site Status

Royal Papworth Hospital NHS Foundation Trust

Cambridge, Cambridgeshire, United Kingdom

Site Status

Guy's and St Thomas Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Canada Czechia France Germany New Zealand Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Scurt FG, Bose K, Mertens PR, Chatzikyrkou C, Herzog C. Cardiac Surgery-Associated Acute Kidney Injury. Kidney360. 2024 Jun 1;5(6):909-926. doi: 10.34067/KID.0000000000000466. Epub 2024 May 1.

Reference Type DERIVED
PMID: 38689404 (View on PubMed)

Thielmann M, Corteville D, Szabo G, Swaminathan M, Lamy A, Lehner LJ, Brown CD, Noiseux N, Atta MG, Squiers EC, Erlich S, Rothenstein D, Molitoris B, Mazer CD. Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study. Circulation. 2021 Oct 5;144(14):1133-1144. doi: 10.1161/CIRCULATIONAHA.120.053029. Epub 2021 Sep 3.

Reference Type DERIVED
PMID: 34474590 (View on PubMed)

Hinze C, Karaiskos N, Boltengagen A, Walentin K, Redo K, Himmerkus N, Bleich M, Potter SS, Potter AS, Eckardt KU, Kocks C, Rajewsky N, Schmidt-Ott KM. Kidney Single-cell Transcriptomes Predict Spatial Corticomedullary Gene Expression and Tissue Osmolality Gradients. J Am Soc Nephrol. 2021 Feb;32(2):291-306. doi: 10.1681/ASN.2020070930. Epub 2020 Nov 25.

Reference Type DERIVED
PMID: 33239393 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

QRK309

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.